Active Biotech - Rebound alter Schwede?!

Ganz interessant vor allem dies:




Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial - See more at: http://www.activebiotech.com/...?pressid=1931462#sthash.kQhdrO8F.dpuf  

 

 

 

 

 

HV heute
https://ml-eu.globenewswire.com/Resource/Download/...2e2-c440f0d24503
 

"Wie bereits kommuniziert, erwarteten wir, in der ersten Hälfte dieses Jahres Daten aus der laufenden klinischen Phase Ib/II-Studie mit Naptumomab in Kombination mit Checkpoint-Inhibition bei Patienten mit fortgeschrittenen soliden Tumoren präsentieren zu können. Die Studie wurde dahingehend ergänzt, dass auch die Vorbehandlung mit Obinutuzumab untersucht wird, um dessen Wirkung auf die Anti-Antikörper (ADAs) gegen Naptumomab zu beurteilen. Die Rekrutierung für die Studie läuft noch, und wir werden Sie auf dem Laufenden halten, sobald die Ergebnisse vorliegen. Weitere Informationen über die Studie finden Sie unter ClinicalTrials.gov: NCT03983954.

Außerdem laufen die Vorbereitungen für den Beginn der bereits kommunizierten Phase-IIa-Studie in Kombination mit Docetaxel bei Patienten mit nicht-kleinzelligem Lungenkrebs. Weitere Informationen zu dieser Studie finden Sie unter ClinicalTrials.gov: NCT04880863.

"Wir sind sehr erfreut über das Engagement, das NeoTX für das Naptumomab-Programm aufbringt, und wir freuen uns darauf, über den Fortgang des Projekts zu berichten", sagte Helén Tuvesson, CEO von Active Biotech."

Übersetzt mit www.DeepL.com/Translator (kostenlose Version)
---

https://www.ariva.de/news/...es-status-update-of-its-clinical-9642251
 

Sonntag, 03.10.2021 21:30 von GlobeNewswire |
"Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been treated with increasing doses of tasquinimod, which was generally well tolerated. The optimal dose and schedule of tasquinimod, when used as a single agent in patients with multiple myeloma has been established at 1 mg per day after a one-week run in of 0.5 mg daily. This is similar to the treatment schedule used in previous studies of tasquinimod.
The trial will now advance to a previously planned combination part, in which treatment with tasquinimod will be tested in patients with multiple myeloma together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd). Once an optimal dose and schedule of tasquinimod for the IRd combination is established, an expansion cohort will be recruited to further document the biological activity of tasquinimod in myeloma patients. Key secondary endpoints will include antimyeloma activity using the response criteria of the International Myeloma Working Group...."
https://www.ariva.de/news/...quinimod-clinical-development-in-9796239
 

Kurs an der OMX (in Schwedischen Kronen)

http://www.nasdaqomxnordic.com/aktier/microsite?Instrument=SSE877

Kommt endlich Volumen rein :)
 

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
October 20, 2021 07:00 (CEST)
https://www.activebiotech.com/en/media/pressreleases/?id=2316994
"Lund, October 20, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox (naptumomab), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

The phase IIa, open label trial in US will assess naptumomab in combination with docetaxel in patients who had been previously treated with checkpoint inhibitors and have advanced or metastatic NSCLC.  The primary endpoint is objective response rate as measured by RECIST 1.1 criteria.  The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics, and pharmacodynamics. For more information about the trial, visit https://clinicaltrials.gov. NCT04880863.

“We are very pleased that NeoTX takes the next step in the development of Naptumomab in NSCLC, a disease with a high unmet medical need, and are excited to follow the progress of the trial.” says Helén Tuvesson, CEO, Active Biotech AB."
 

https://www.activebiotech.com/sv/press/pressmeddelanden/?id=2327106
-

https://www.realtid.se/telegram/...rterar-en-okad-rorelseforlust-i-q3
"Veröffentlicht am 2021-11-04
Das Forschungsunternehmen Active Biotech meldet für das dritte Quartal keine Einnahmen wie geplant. Betriebsverlust erhöht.

Das Betriebsergebnis betrug -11,3 MSEK (-8,3).

Das Ergebnis nach Steuern betrug -11,2 MSEK (-8,2), das Ergebnis je Aktie -0,05 MSEK (-0,05).

Der Cashflow aus betrieblicher Tätigkeit belief sich auf -31,0 MSEK (-27,9).

Die Zahlungsmittel und Zahlungsmitteläquivalente beliefen sich auf 68,4 (30,9) MSEK.

Die Vorstandsvorsitzende Helén Tuvesson ist von den Fortschritten bei den Projekten des Unternehmens begeistert.

"Seit wir unsere neue Ausrichtung für 2020 vorgestellt haben, bereiten wir uns auf den neuen Plan vor und leiten die entsprechenden Aktivitäten ein. Ich freue mich sehr, dass wir jetzt erste Ergebnisse sehen, und ich freue mich darauf, die Pläne entsprechend der neuen Ausrichtung zu vollenden. Wir haben die ersten ermutigenden Ergebnisse aus der laufenden Tasquinimod-Studie beim Multiplen Myelom und den Start einer neuen Kombinationsstudie mit Naptumomab und Docetaxel bei Lungenkrebs bekannt gegeben - zwei Krebsarten, bei denen der medizinische Bedarf trotz der Verfügbarkeit neuer Therapien immer noch hoch ist", schreibt Tuvesson in der Erklärung des CEO.

Active Biotech, SEKmQ3-2021Q3-2020VeränderungNettoumsatz00Betriebsergebnis-11,3-8­,3Nettoergebnis-11,2-8,2Gewinn je Aktie, SEK-0,05-0,05Cashflow aus betrieblicher Tätigkeit-31,0-27,9Liquidität und Zahlungsmitteläquivalente68,430,9121,4%"

Übersetzt mit www.DeepL.com/Translator (kostenlose Version)

-

Dem Kurs gefällts
http://www.nasdaqomxnordic.com/aktier/...iotech&ISIN=SE0001137985
 

https://www.activebiotech.com/en/media/pressreleases/?id=2327571

"New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
November 4, 2021 14:00 (CET)
Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia, December 11-14, 2021.

The results that will be highlighted in the poster presentations are part of Active Biotech’s program to address the unmet medical needs to treat hematological malignances, with focus on multiple myeloma. Currently, a clinical phase Ib/IIa trial in patients with multiple myeloma is ongoing.

Information on the presentations:
P 1595. Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo. Poster session 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I. Dec 11, 2021, 5.30-7.30 p.m. R. Fay et al., Vrije University, Brussels, Belgium.

P 2596. Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro Poster session 636. Myelodysplastic Syndromes – Basic and Translational: Poster II., Dec 12, 2021, 6.00-8.00 p.m. M. Wobus et al., University Hospital Dresden, Germany.

Abstracts will be available at the ASH website from 9 am Eastern time (2 pm Central European Time) on November 4, 2021."
 

Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021
November 30, 2021 15:00 (CET)

Lund, Sweden — November 30, 2021 – Active Biotech and its partner NeoTX announced that the preclinical data on naptumomab enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C.

Clinical CAR-T therapy currently has limited efficacy against solid tumors due to low trafficking to the tumor, limited cell expansion in patients, tumor antigen heterogeneity, and an immunosuppressive microenvironment. The presented data shows that naptumomab generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro.

The ability of naptumomab to activate T cells outside of the immunosuppressive microenvironment, promote T cell infiltration into the tumor and induce long-term memory responses strongly suggests that the combination of CAR-T cells with naptumomab may overcome the limited effect of CAR-T therapy against solid tumors. To access the presented poster, please click here.
See also www.neotx.com for NeoTX’s communication related to this information.
https://www.activebiotech.com/en/...s-now-available-on-neotx-website/

https://neotx.com/wp-content/uploads/2021/11/...oster2021Final-FF.pdf
Conclusion;
Our studies show that NAP generates more potent CAR-T cells and acts
synergistically with CAR-T against tumor cell lines in vitro. The ability of
NAP administration to activate T cells outside of the immunosuppressive
microenvironment (in the lymphoid organs), promote T cell infiltration into
the tumor and induce long-term memory responses, strongly suggests that
combination of CAR-T cells with NAP may overcome the limited effect of
CAR-T therapy against solid tumors. NAP is currently being evaluated in
clinical studies in combination with durvalumab [NCT03983954] and
docetaxel [NCT04880863]
 

"First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  
December 10, 2021 08:30 (CET)
https://www.activebiotech.com/en/media/pressreleases/?id=2349825
Lund, December 10, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod.

Laquinimod is being developed as a new treatment for non-infectious non-anterior uveitis and has the potential to be used in the first line treatment as an add-on to steroids as well as in the second line treatment for patients that have failed steroid treatment.

Preclinical data suggest that laquinimod may influence inflammatory eye diseases when given both as a tablet and directly onto the eye. Active Biotech has developed an eye-drop formulation of laquinimod with the aim to use it for the treatment of inflammatory eye diseases, initially in patients with non-infectious non-anterior uveitis. These are patients who lack sufficiently effective and safe treatments and in addition, there is currently no eye-drop treatment available.

A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects. The primary endpoint of the study is to determine the safety and tolerability of laquinimod eye-drops after single and repeat doses. Secondary endpoints include eye toxicity and pharmacokinetics.

I am happy to report that we have initiated the clinical development of the new formulation of laquinimod and I look forward to review the results from this initial safety study. Laquinimod has the potential to be used in the treatment of serious eye diseases, which is underscored by preclinical data. In the next step we will continue the clinical investigation of laquinimod in patients with uveitis, with the goal to provide a new treatment to this sight-threatening eye disease” said Helén Tuvesson, CEO of Active Biotech."  

"Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma
February 7, 2022 08:30 (CET) REGULATORY
https://www.activebiotech.com/en/...-tasquinimod-in-multiple-myeloma/
Lund Sweden, February 7, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma. In this part of the study treatment with tasquinimod will be tested together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd).

Once an optimal dose and schedule of tasquinimod for the IRd combination is established, an expansion cohort will be recruited to further document the biological activity of tasquinimod in myeloma patients. Key secondary endpoints will include antimyeloma activity using the response criteria of the International Myeloma Working Group.

As previously communicated, the optimal dose and schedule of tasquinimod, when used as a single agent in patients with multiple myeloma, was established at 1 mg per day after a one-week run in of 0.5 mg daily. Tasquinimod was generally well tolerated and the established treatment schedule and safety profile of tasquiniomod in myeloma patients resembled that previously demonstrated in solid tumors.

The study is conducted in an academic partnership with the Abramson Cancer Center of the University of Pennsylvania, with Dr. Dan Vogl as principal investigator. Detailed information about the study is available on clinicaltrials.gov (NCT04405167).

“We are pleased to have enrolled the first patient to the combination part of the study where tasquinimod will be combined with a standard anti-myeloma treatment regimen. Our preclinical laboratory models suggest that this combination strategy may be a particularly effective way to utilize tasquinimod in myeloma therapy,” said Dr. Dan Vogl, Principal Investigator.

“The use of tasquinimod in combination with treatments used for earlier stage patients, is aligned with our current understanding of the mode of action of tasquinimod being able to block tumor sustaining signals from the bone marrow microenvironment. We are enthusiastic to follow the progress of the study ” said Helén Tuvesson, CEO, Active Biotech AB.

For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 08.30 am CET on February 7, 2022."  

"Active Biotech: Year End Report 2021
February 9, 2022 22:30 (CET) REGULATORY
https://www.activebiotech.com/en/...e-biotech-bokslutsrapport-2021-2/
FOURTH QUARTER IN BRIEF
In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular proved to be a busy period, with continued strong development with all the prioritized projects in our portfolio.

Tasquinimod
Clinical development in multiple myeloma advanced into combination therapy following completion of the initial phase of the ongoing trial in the US (Oct 3)
Preclinical tasquinimod data presented at ASH 2021 (Dec 11-12)
Naptumomab
Active Biotech and NeoTX announced that the first patient had been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) (Oct 20)
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021 (Nov 12)
Laquinimod
First subject dosed in phase I clinical study with eye drop formulation of laquinimod  (Dec 10)
EVENTS AFTER THE END OF THE PERIOD
Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)
First patient dosed in the combination part of the Phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)
Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9)"  

https://ml-eu.globenewswire.com/Resource/Download/...0d5-006f6dd2b20c
 

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
May 18, 2022 15:00 (CEST)
https://www.activebiotech.com/en/media/pressreleases/?id=2446074
 

http://www.nasdaqomxnordic.com/aktier/...iotech&ISIN=SE0001137985
 

0,13€

--
Korrektur zu #75
Aber kann ja noch werden.. ;)
 

Preclinical data with tasquinimod in MDS to be presented at ASH 2022
11/03/2022 | 09:01am EST
https://www.marketscreener.com/quote/stock/...d-at-ASH-2022-42194313/
Lund, November 3, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that an abstract with preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), has been accepted for presentation at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10-13, 2022 (ASH 2022). The ASH 2022 abstracts were released today, November 3rd, 2022.

The abstract, titled Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells will be presented by Dr. Manja Wobus, University Hospital Dresden, Germany.

The abstract is the result of a collaboration between Active Biotech and an academic group in Dresden, Germany which aims at addressing the unmet medical need to treat MDS. The presented data show that a subpopulation of mesenchymal stromal cells, i.e. CD271+ MSC’s, is responsible for the diminished hematopoietic support. Tasquinimod modulates the function of these cells and thereby enhances their potential to support hematopoiesis in vitro.

“These new preclinical results suggest that tasquinimod treatment has the potential to increase the hematopoiesis in MDS patients. We are exited to get the opportunity to present our data at such a prestigious conference as ASH, which manifests the external scientific interest in the project,” said Helén Tuvesson, CEO of Active Biotech.

Information on the presentation:

P 1753. Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells. Poster session 636. Myelodysplastic Syndromes – Basic and Translational: Poster I. Dec 10, 2022, 5:30-7:30 PM. Ernest N. Morial Convention Center, Hall D. Dr. M. Wobus et al., University Hospital Dresden, Germany.

The accepted abstract will be available on the ASH website from 9:00 am Eastern Daylight Time (2:00pm Central European Time) on November 3, 2022.

This information was submitted for publication, through the agency of the contact person set out above, at 15.00 pm CET on November 3, 2022.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com  

Die HV lief offenbar gut... ;)
https://www.activebiotech.com/en/...l-meeting-of-active-biotech-ab-4/

+23% / auf nun 0,8 SKr.
https://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE877
 

Heute +34%
(Zwischenzeitlich schon ü 1,-Skr)
https://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE877

"Präklinische Tasquinimod-Daten bei Myelofibrose für mündliche Präsentation auf der ASH 2023 ausgewählt
02.11.2023 14:30 (MEZ)
Lund, 2. November 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) gab heute bekannt, dass zwei Abstracts mit präklinischen Daten für Tasquinimod bei Myelofibrose und myelodysplastischem Syndrom (MDS) zur Präsentation auf der 65. Jahrestagung der American Society of Hematology in San Diego angenommen wurden , 9. – 12. Dezember 2023 (ASH 2023). Die Zusammenfassung, die die Wirkung von Tasquinimod bei Myelofibrose zeigt, wurde für einen mündlichen Vortrag ausgewählt. Die angenommenen Abstracts für ASH 2023 wurden heute, 2. November 2023, veröffentlicht.

Die Zusammenfassung mit dem Titel „ Präklinische Studien zum Nachweis der Wirksamkeit von Tasquinimod in Modellen fortgeschrittener myeloproliferativer Neoplasien (MPN) in der Blastenphase“ wird im Rahmen einer mündlichen Podiumspräsentation von Dr. Warren Fiskus, PhD MD Anderson Cancer Center, Texas, USA. Die Zusammenfassung ist ein Ergebnis der Zusammenarbeit zwischen Active Biotech und der Forschungsgruppe von Professor Kapil N. Bhalla bei MD Anderson und zielt in erster Linie darauf ab, die Mechanismen und Wirkungen von Tasquinimod bei Myelofibrose zu klären. Die vorzulegenden Daten belegen die Wirksamkeit von Tasquinimod als Monotherapie und in Kombination mit Erstlinientherapien in Modellen für fortgeschrittene Myelofibrose.

Darüber hinaus wird die Zusammenfassung mit dem Titel „ Tasquinimod verbessert die Erythropoese und mildert den Knochenverlust bei myelodysplastischen Mäusen“ als Poster von Dr. Manja Wobus, Universitätsklinikum Dresden, Deutschland. Die Zusammenfassung stammt aus unserer Zusammenarbeit mit Dr. Wobus in Dresden und zeigt den ersten Beweis einer In-vivo-Wirkung von Tasquinimod in einem Mausmodell von MDS durch eine deutliche Verbesserung der Anzahl roter Blutkörperchen und eine Verringerung des Knochenschwunds.

„Die vorzulegenden Daten legen nahe, dass die Behandlung mit Tasquinimod sowohl als Monotherapie als auch in Kombination mit anderen Therapien das Potenzial hat, eine breite Wirkung bei Myelofibrose und MDS zu erzielen. Wir freuen uns sehr und fühlen uns geehrt, die Gelegenheit zu haben, unsere Daten auf einer so prestigeträchtigen Veranstaltung präsentieren zu dürfen.“ Konferenz als ASH, was das externe wissenschaftliche Interesse an Tasquinimod im Krankheitsbereich zeigt“, sagt Helén Tuvesson, CEO von Active Biotech. Biotech.

Informationen zu den Vorträgen

Veröffentlichungsnummer: 741 Präklinische Studien zum Nachweis der Wirksamkeit von Tasquinimod in Modellen fortgeschrittener myeloproliferativer Neoplasien (MPN) in der Blastenphase, Warren Fiskus et al.
Sitzungsname: 631. Myeloproliferative Syndrome und chronische myeloische Leukämie: Grundlagen und Translation: Stromal-Immun- und Signalkontext
Sitzungsdatum: Montag, 11. Dezember 2023
Sitzungszeit: 10:30 – 12:00 Uhr
Präsentationszeit: 11:00 Uhr
Raum: San Diego Convention Center, Ballsaal 20AB

Veröffentlichungsnummer: 2798 Tasquinimod verbessert die Erythropoese und mildert den Knochenverlust bei myelodysplastischen Mäusen, Manja Wobus et al.
Sitzungsname: 604. Molekulare Pharmakologie und Arzneimittelresistenz: Myeloische Neoplasien: Poster II
Sitzungsdatum: Sonntag, 10. Dezember 2023
Präsentationszeit: 18:00 – 20:00 Uhr
Raum: San Diego Convention Center, Halls GH

Die Abstracts werden auf der Website von ASH verfügbar sein 09:00 Uhr Eastern Time (14:00 Uhr MEZ) am 2. November 2023..."
https://www.activebiotech.com/sv/mfn_news/...resentation-pa-ash-2023/


 

Q3/23
https://view.news.eu.nasdaq.com/...e3c7871a&lang=en&src=micro
"THIRD QUARTER IN BRIEF
Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11)
Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech’s website (September 13)

EVENTS AFTER THE END OF THE PERIOD
Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023 (November 2)
The board of directors resolved on November 9, based on the authorization from the general meeting, to carry out a rights issue of approximately SEK 51 million (before issue costs) to secure financing of the ongoing and planned development programs for tasquinimod and laquinimod"
---

KE voraus...
https://view.news.eu.nasdaq.com/...1bdf828d&lang=en&src=micro
"The board of directors of Active Biotech AB (publ) (”Active Biotech” or the ”Company”) has, based on the authorisation from the general meeting, resolved on a rights issue of approximately SEK 51 million, before transaction costs. Not more than 113,633,436 new shares are issued through the rights issue. The subscription price amounts to SEK 0.45 per share and the right to subscribe for new shares shall vest in the Company’s shareholders with pre-emptive rights, whereby seven existing shares entitle to subscription for three new shares. The proceeds from the rights issue are intended to provide the Company with the financial stability needed to pursue the planned clinical research activities related to its prioritized programs, await the outcome of the ongoing clinical studies and conduct negotiations with partners. The Company has entered, free of charge, subscription commitments and issue guarantees of approximately SEK 27.6 million in relation to the rights issue..."
 

https://www.nasdaqomxnordic.com/aktier/...eId=1&Instrument=SSE877
Dieses Jahr schon über +100%

Hier mal die aktuelle Präsentation
https://www.activebiotech.com/wp-content/uploads/..._Presentation.pdf
Finanziell sieht das ziemlich schlecht aus (Seite 26)

aber besonders interessant, Seite 25